AU678858B2 - Controlled release potassium dosage form - Google Patents
Controlled release potassium dosage form Download PDFInfo
- Publication number
- AU678858B2 AU678858B2 AU78757/94A AU7875794A AU678858B2 AU 678858 B2 AU678858 B2 AU 678858B2 AU 78757/94 A AU78757/94 A AU 78757/94A AU 7875794 A AU7875794 A AU 7875794A AU 678858 B2 AU678858 B2 AU 678858B2
- Authority
- AU
- Australia
- Prior art keywords
- dosage unit
- micropellets
- unit according
- coating
- ethylcellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title claims description 16
- 239000011591 potassium Substances 0.000 title claims description 16
- 229910052700 potassium Inorganic materials 0.000 title claims description 16
- 238000013270 controlled release Methods 0.000 title description 4
- 239000002552 dosage form Substances 0.000 title description 2
- 238000000576 coating method Methods 0.000 claims abstract description 39
- 239000011248 coating agent Substances 0.000 claims abstract description 37
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 33
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 27
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 27
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 27
- 239000001103 potassium chloride Substances 0.000 claims abstract description 15
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 15
- 239000001087 glyceryl triacetate Substances 0.000 claims abstract description 14
- 235000013773 glyceryl triacetate Nutrition 0.000 claims abstract description 14
- 229960002622 triacetin Drugs 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000004014 plasticizer Substances 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 6
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000008199 coating composition Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims 3
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 claims 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 210000004877 mucosa Anatomy 0.000 abstract description 4
- 229910001414 potassium ion Inorganic materials 0.000 abstract description 4
- 150000002500 ions Chemical class 0.000 abstract description 3
- 239000012530 fluid Substances 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000011253 protective coating Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 8
- 239000008188 pellet Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 229940070017 potassium supplement Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000282337 Nasua nasua Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/131,118 US5397574A (en) | 1993-10-04 | 1993-10-04 | Controlled release potassium dosage form |
| US131118 | 1993-10-04 | ||
| PCT/US1994/010580 WO1995009617A1 (en) | 1993-10-04 | 1994-09-23 | Controlled release potassium dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7875794A AU7875794A (en) | 1995-05-01 |
| AU678858B2 true AU678858B2 (en) | 1997-06-12 |
Family
ID=22447956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU78757/94A Ceased AU678858B2 (en) | 1993-10-04 | 1994-09-23 | Controlled release potassium dosage form |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5397574A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0804172B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH09510430A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE211649T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU678858B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2172624A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69429632T2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ274646A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1995009617A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| HU221435B (en) * | 1998-02-20 | 2002-10-28 | Egyt Gyogyszervegyeszeti Gyar | Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production |
| CA2394588A1 (en) * | 1999-12-16 | 2001-06-21 | Melissa Gantt | Controlled release kcl tablet formulations |
| EP1395224A4 (en) * | 2001-05-22 | 2005-10-26 | Euro Celtique | INVIOLABLE ORAL DOSAGE FORM |
| US6837696B2 (en) * | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
| MXPA04002891A (es) * | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Composicion farmaceutica a base de pasta de azucar. |
| US6780437B2 (en) * | 2001-10-23 | 2004-08-24 | Upsher-Smith Laboratories, Inc. | Coated potassium chloride granules and tablets |
| US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| WO2003077897A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| US20040156844A1 (en) * | 2002-05-22 | 2004-08-12 | Curtis Wright | Tamper resistant oral dosage form |
| US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| MXPA05008033A (es) * | 2003-01-28 | 2006-04-28 | Collegium Pharmaceutical Inc | Composiciones de milnacipran en forma de multiparticulas para administracion oral. |
| US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
| US8124598B2 (en) * | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
| US20100160274A1 (en) * | 2007-09-07 | 2010-06-24 | Sharon Sageman | 7-KETO DHEA for Psychiatric Use |
| US20090181094A1 (en) * | 2008-01-15 | 2009-07-16 | Eric Yueh-Lang Sheu | Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents |
| JP2011529923A (ja) | 2008-08-06 | 2011-12-15 | ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド | 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法 |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| US20150133516A1 (en) | 2013-11-13 | 2015-05-14 | Brian K. Adams | Methods and Compositions for Treating ADHD |
| HK1254594A1 (zh) | 2015-07-02 | 2019-07-26 | University Of Louisville Research Foundation, Inc. | 用於递送mirna的源自可食用植物的微囊泡组合物和用於治疗癌症的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798724A (en) * | 1985-06-24 | 1989-01-17 | Ciba-Geigy Corporation | Solid, stable dosage forms with an elastic film coating |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL120093C (cg-RX-API-DMAC7.html) * | 1958-07-24 | |||
| DK152744C (da) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat |
| IT1191050B (it) * | 1982-10-27 | 1988-02-24 | Pietro Tommaso Tessitore | 2(1-alchil-5-nitro)-imidazolil-1-(2-idrossi-5-alchil)-fenil-carbinoli,loro metodo di preparazione e composizioni farmaceutiche che li contengono |
| JPS61151109A (ja) * | 1984-12-26 | 1986-07-09 | Lion Corp | 毛髪化粧料組成物 |
| JPS61171413A (ja) * | 1985-01-17 | 1986-08-02 | Pola Chem Ind Inc | 養毛料 |
| IE59066B1 (en) * | 1985-02-19 | 1993-12-15 | Key Pharma | Controlled release potassium chloride |
| CA1270765A (en) * | 1985-02-19 | 1990-06-26 | Charles Hsiao | Controlled release potassium chloride |
| JPS62175417A (ja) * | 1986-01-27 | 1987-08-01 | Kanebo Ltd | 養毛化粧料 |
| JPS6396106A (ja) * | 1986-10-11 | 1988-04-27 | Shiseido Co Ltd | 化粧料 |
| US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5035898A (en) * | 1987-11-27 | 1991-07-30 | Schering Corporation | Potassium/magnesium supplement |
| IE60383B1 (en) * | 1988-05-27 | 1994-07-13 | Elan Corp Plc | Controlled release pharmaceutical formulation |
| JPH02111710A (ja) * | 1988-10-20 | 1990-04-24 | Akio Fujikawa | 化粧料組成物 |
| JPH03206021A (ja) * | 1990-01-08 | 1991-09-09 | Kanebo Ltd | 養毛化粧料 |
| JP2969866B2 (ja) * | 1990-08-29 | 1999-11-02 | 大正製薬株式会社 | 発毛剤 |
| JPH04308523A (ja) * | 1991-04-04 | 1992-10-30 | Kanebo Ltd | 養毛化粧料 |
| US5200195A (en) * | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
| US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
-
1993
- 1993-10-04 US US08/131,118 patent/US5397574A/en not_active Expired - Lifetime
-
1994
- 1994-09-23 EP EP94929839A patent/EP0804172B1/en not_active Expired - Lifetime
- 1994-09-23 WO PCT/US1994/010580 patent/WO1995009617A1/en not_active Ceased
- 1994-09-23 AU AU78757/94A patent/AU678858B2/en not_active Ceased
- 1994-09-23 CA CA002172624A patent/CA2172624A1/en not_active Abandoned
- 1994-09-23 AT AT94929839T patent/ATE211649T1/de not_active IP Right Cessation
- 1994-09-23 DE DE69429632T patent/DE69429632T2/de not_active Expired - Fee Related
- 1994-09-23 JP JP7510821A patent/JPH09510430A/ja active Pending
- 1994-09-23 NZ NZ274646A patent/NZ274646A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798724A (en) * | 1985-06-24 | 1989-01-17 | Ciba-Geigy Corporation | Solid, stable dosage forms with an elastic film coating |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995009617A1 (en) | 1995-04-13 |
| ATE211649T1 (de) | 2002-01-15 |
| AU7875794A (en) | 1995-05-01 |
| DE69429632T2 (de) | 2002-11-14 |
| DE69429632D1 (de) | 2002-02-14 |
| EP0804172A1 (en) | 1997-11-05 |
| EP0804172B1 (en) | 2002-01-09 |
| JPH09510430A (ja) | 1997-10-21 |
| NZ274646A (en) | 1997-02-24 |
| US5397574A (en) | 1995-03-14 |
| EP0804172A4 (cg-RX-API-DMAC7.html) | 1997-11-05 |
| CA2172624A1 (en) | 1995-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU678858B2 (en) | Controlled release potassium dosage form | |
| AU676229B2 (en) | Stable extended release oral dosage composition | |
| US4424235A (en) | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor | |
| CA1318602C (en) | Controlled release combination of carbidopa/levodopa | |
| US7374781B2 (en) | Sustained release formulations containing acetaminophen and tramadol | |
| RU2236847C2 (ru) | Композиции в виде множества частиц с модифицированным высвобождением | |
| CN1119993C (zh) | 醋氨酚、假麻黄碱、扑尔敏和可有可无的美沙芬的旋转制粒及包衣 | |
| RU2001111887A (ru) | Композиция в виде множества частиц с модифицированным высвобождением | |
| ZA200209525B (en) | Oral Pharmaceutical composition with controlled release and prolonged absorption. | |
| JPH0753365A (ja) | γ−ヒドロキシ酪酸塩による制御放出能をもつ薬化学組成物 | |
| JPS6116368B2 (cg-RX-API-DMAC7.html) | ||
| KR20030013460A (ko) | 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형 | |
| JPS62501845A (ja) | 制御放出塩化カリウム | |
| US5589190A (en) | Sustained-release compositions of alfuzosin hydrochloride | |
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| CA2606740A1 (en) | Quinine-containing controlled-release formulations | |
| EP1109535B1 (en) | Extended release acetaminophen | |
| DK165123B (da) | Fremgangsmaade til mekanisk bearbejdning af cobalt-holdige metaller samt med vand blandbart koncentrat til brug ved fremgangsmaaden | |
| Radhika et al. | Formulation and Evaluation of Sustained Release Matrix Tablets of Glipizide: Sustained release matrix tablets of glipizide | |
| KR20080041669A (ko) | 매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물 | |
| JP3170855B2 (ja) | イブプロフェン含有解熱鎮痛剤 | |
| US4863743A (en) | Controlled release potassium chloride | |
| JP3122478B2 (ja) | 下部消化管放出型経口製剤 | |
| JP3282832B2 (ja) | 持続性錠剤 | |
| JPH08239327A (ja) | 慢性骨格筋疼痛の予防又は治療剤 |